Oncology Publications, Abstracts, and Posters
Monogram Oncology, part of Monogram Biosciences, presented nine abstracts at the American Society of Clinical Oncology and San Antonio Breast Cancer Symposium meetings in 2007. Monogram Oncology's abstracts focused on demonstrating the clinical utility and flexibility of its proprietary VeraTag™ technology, a novel proximity-based technology which quantifies functional protein-protein interactions and protein expression.The studies listed below are available to download.
| Development of novel-proximity based immunoassays for activated HER1, HER2, and HER1-HER2 heterodimers in formalin-fixed, paraffin embedded (FFPE) cells |
| Lisa DeFazio Eli, Kristi Frankson, Trang Dao-Pick, Jerry Wallweber, Tam Dang, Rajiv Dua, Laurie Goodman, Gordon Parry, John Winslow 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008 Poster #88 |
| Download PDF |
| Development of highly quantitative, sensitive, and reproducible assays for the detection of EGFR/HER1 and ErbB3/HER3 in formalin-fixed, paraffin-embedded |
| Yining Shi*, Ali Mukherjee*, *Jennifer Weston, Jolly Bose, Xuan-Thao Nguyen, Agnes Paquet, Colombe Chappey, Gordon Parry, Laurie J. Goodman 20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008 Poster #103 |
| Download PDF |
| Comparison of Central HER-2 Tests with Quantitative HER-2 Expression and HER-2 Homodimer Measurements Using a Novel Proximity Based Assay |
| W Huang, E Perez et al. Poster #40, College of American Pathology Meeting 2008 |
| Download PDF |
| Total HER2 and HER2 homodimer levels predict response to trastuzumab |
|
K. Leitzel, A. Lipton, et al. American Society of Clinical Oncology 44th Annual Meeting, Chicago, IL June 2, 2008 Oral Presentation |
|
Download Slide Deck Download PDF |
| The ASCO/CAP Guidelines for HER2 Testing in Breast Cancer |
| Wolff, et al. Journal of Clinical Oncology Vol. 25, Number 1, January 2007 |
| Download PDF |
| HER2 expression and HER2-HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy. |
| M. Bates, et al. 2007 ASCO Annual Meeting Proceedings Poster #10577 |
| Download PDF |
|
Increased detection of breast cancer markers human epidermal growth factor receptor dimer and downstream signaling proteins utilizing the VeraTag technology with dextran modified antibodies.
Wallweber et al. 30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 12- 16, 2007. Abstract # 5002 |
| Download PDF |
|
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer.
M. Toi, J. Sperinde, W. Huang, et al. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol. 25, (18S), 2007: 1025 |
| Download PDF |
|
Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines.
R. Dua, P. Nhonthachit, C. Rinehart, et al. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol.25, (18S), 2007 |
| Download PDF |
